How We Look for Big Problems Before They Show Themselves
This part of the book is about catching trouble early. Many of the worst illnesses do not hurt at first. By the time you feel sick, it can be too late. So we use simple tests, scans, and blood checks to look for these things before you ever feel them. Think of it like a watch-tower for your whole body.
Why We Look So Hard
I have grown older and so have my patients — along with many new people who come to see me for the first time.
I do not like to lose. But I have learned to be humble. All around us there is now a wave of long, deadly illnesses. The worst of these are the cancers and the diseases that slowly harm the brain, like Alzheimer’s. Once these illnesses begin to show signs, regular medicine often has no real answer. And sometimes the treatment is as hard on the body as the disease itself.
Many of my new patients come to me after their other treatments have stopped working. Some have been told there is nothing more to try. I hear so many sad stories. This is most true with the fastest, meanest cancers, like cancer of the pancreas. At first, a person feels only small aches that seem like nothing. Then, all at once, those small aches burst into terrible pain — and sometimes a fight for life.
This is why we need an early warning. Think of the loud sirens that warn a town when a big storm is coming. They give people time to act, find shelter, and stay safe. We can do the very same thing for your body.
Your best chance to beat these deadly illnesses is the plan we have followed all through this book. First, we calm and repair the body’s matrix — the living net that holds your cells in place. (Its full name is the extracellular matrix.) Then we add one more step: we look early. We use safe scans. And we use special blood tests that can spot tiny bits of cancer DNA floating in your blood.
In this part of the book, I will share my plan for finding these illnesses early — before you ever feel sick.
Here is a true story that shows why this matters. Three different times, a patient came in for a heart scan called a Coronary Calcium Score. That scan looks at the heart, but it also shows part of the lungs. All three times, the scan found a small, early lung cancer. Each one was taken out with surgery. None of them needed chemo. And all three people did very well.
This matters a great deal. Lung cancer is more common than you think in women — even those who never smoked. It takes more women’s lives than breast cancer does. We went looking for one problem (hard plaque in the heart) and found a different, hidden killer instead. This kind of cancer is usually not caught until it has already spread to other parts of the body.
So, let’s begin. Let’s not wait until it is too late.
Here is the truth that many people do not know: about 1 in every 2 people will get cancer in their lifetime. That is half of all of us. And only 4 kinds of cancer have a routine screening test that most doctors do. Those are breast, colon, cervix, and (for some people) lung cancer.
Of all the cancers we find each year, only about 14% are caught by those routine tests. That means 86% of cancers are found some other way — usually after a person starts to feel sick. And by then, many of these cancers are very hard to cure.

Figure 1. Routine screening tests find only a small slice of the cancer pie.
Some of the worst cancers are the ones routine tests do not look for. Cancer of the pancreas, the brain (called glioblastoma), and many kinds of lung cancer often have very poor outcomes once symptoms show up. So we want to find them long before that.
Cancer is not the only quiet killer. There are others:
- Heart disease — plaque builds up inside the heart’s arteries for years without making you feel a thing. The first warning sign is often a heart attack.
- Brain aneurysms — a thin, weak spot on a blood vessel in the brain. It can sit there for decades. When it bursts, the result can be deadly or leave lasting harm.
- Aortic aneurysms — the aorta is the big pipe that carries blood from your heart to the rest of your body. A weak spot in this pipe can grow slowly and burst suddenly. Most people have no idea it is there.
- Quiet kidney, liver, and thyroid trouble — these organs can get sick over many years before they speak up.
Here is a number that surprises most people: more women die from heart disease than from any kind of cancer. In fact, heart disease is the number one cause of death for women in the United States. About 1 in every 5 women who die in this country die from heart disease. Yet only about half of women know this. That is why we look hard at the heart — not just at things people worry about more often.
The Whole-Body Scan
One of the best tools we have is a whole-body MRI scan. MRI stands for magnetic resonance imaging. It uses a big, strong magnet — not X-rays — to take pictures of the inside of your body.
Why we like it:
- No X-rays. No radiation. That means you can have it again and again over the years without worry.
- No needles. No dye is needed in most cases. You just lie still and the machine does its work.
- It looks at almost every part of you. Brain, neck, lungs, heart area, liver, kidneys, pancreas, spleen, ovaries or prostate, lymph nodes, the big body arteries, and the bones of the spine and pelvis.
- It can spot up to 500 different conditions. Not just cancer — also aneurysms, cysts, growths, organ problems, and joint trouble.

Figure 2. A whole-body MRI looks at many organs in one visit.
One thing to know: the whole-body MRI does not show calcium in the heart’s arteries. So, we pair it with a different scan, the coronary calcium score, to get the heart story.
How often? For most of our patients, we suggest a whole-body MRI every 1 to 3 years, depending on your family history, your age, and what we have seen before.
The Galleri Blood Test — Looking for Cancer DNA
Cancer cells shed tiny pieces of DNA into the blood, even when they are very small. A test called Galleri can find these pieces. From one blood draw, it can check for signs of more than 50 different kinds of cancer. That includes many cancers that have no other screening test — pancreas, ovary, esophagus, liver, stomach, and more.
How well does Galleri work? In a study of more than 25,000 adults called PATHFINDER 2, finished in 2025, Galleri found about 74% of the 12 most deadly cancers — the ones that cause two out of every three cancer deaths. When added to standard screenings, it found seven times more cancers than standard screenings alone. And its false alarm rate is very low — less than 1 in 200.
What Galleri is not: it is not perfect. It finds about 4 out of 10 cancers overall, and it is better at catching later-stage cancers than very early ones. So we do not use it alone. We use it together with the whole-body MRI and the other screenings you should already be doing — mammogram, colonoscopy, Pap smear, and (for some) low-dose lung CT. Each test catches what the others miss.
How often? Once a year is what we suggest for most of our patients aged 50 and older, or earlier if you have a strong family history of cancer.
Caris Detect — Reading the Whole DNA Code
In 2026, a second cancer blood test became ready to use. It is called Caris Detect. Like Galleri, it needs only one blood draw. Like Galleri, it looks for tiny bits of DNA that a cancer may have shed into your blood. But it looks in a different way.
Here is the difference. Think of your DNA as a very long book of instructions. Galleri checks for small chemical “tags” that sit on certain pages. Caris Detect reads the whole book, cover to cover, many times over. Then a computer adds up many small clues. A changed letter here. A missing page there. A piece torn in an odd way. One small clue alone means little. Many small clues together can point to a hidden cancer.

Figure 3. Most DNA bits in your blood come from healthy cells (blue). A cancer blood test looks for the few that may come from a tumor (orange).
How well does Caris Detect work? In the company’s own study of about 3,000 people, finished in 2026, Caris Detect found a little more than half of Stage 1 cancers and about 2 out of 3 Stage 2 cancers. Stage 1 and Stage 2 are the earliest stages, when a cancer is small and easiest to treat. These are the best early results reported so far for a test of this kind. It also found more early breast and prostate cancers than other blood tests have.
But we must be honest about what we do not know yet. Many people in that study already had signs of illness or a spot on a scan. In healthy people with no signs, the test may not work as well. The study has not yet been checked by outside experts and printed in a medical journal. And no one has tested Caris Detect and Galleri side by side. So we cannot yet say that one is better than the other.
What Caris Detect is not: it is not perfect. It can miss a cancer that is there. It can also sound a false alarm. In a small group of healthy people in the study, about 1 in 100 got a false alarm. In a larger group at higher risk, it was about 4 in 100. And the test does not tell us the stage of a cancer. It only tells us whether to look closer.
What Your Result Means
Your result will be one of three answers:
- No Cancer Signal Detected — nothing unusual was found. This is good news, but it is not an all-clear. You still need your regular screenings.
- Atypical Signal Detected — the test saw something small and unclear. It is not clearly cancer. The test is done again in about 3 months.
- Cancer Signal Detected — the test found a pattern linked to cancer. This is not a diagnosis. The report also points to the part of the body where we should look first. Then we use scans to find out more.

Figure 4. The three results of a Caris Detect test, and what we do next.
Galleri or Caris Detect — Which One?
Both tests do the same job in your watch-tower. Most patients need only one of them each year. We choose together, based on your age, your family story, and your budget.
- Galleri — has been studied the most, in more than 170,000 adults aged 50 and older. It costs about $950. It is weaker at finding the very earliest cancers, and it does not find breast or prostate cancer well.
- Caris Detect — is newer. Its early results look stronger for early cancers. But it rests on one company study so far. It costs about $3,500. It can be ordered for adults aged 21 and older.
Neither test is approved by the FDA yet, and insurance does not pay for them. A word for younger adults: cancer is much less common before age 50. So at a younger age, a positive result is more likely to be a false alarm. We talk this over with you before we test.
How often? Once a year, the same as Galleri.
Gene Tests — The Risk You Were Born With
Some patients ask, “Is this the same as the gene test my sister had?” It is not. There are two very different kinds of DNA tests. They answer two different questions.
The first kind looks at the genes you were born with. You got them from your mother and father. They are the same in almost every cell of your body, and they do not change. A test called MyRisk reads a set of these genes. It looks for a change that makes some cancers more likely. The best known are the BRCA genes. A change in a BRCA gene raises the chance of breast and ovarian cancer.

Figure 5. A gene change you were born with (orange) raises the chance of cancer later in life. It does not mean cancer is there.
A gene change like this is a risk, not a disease. Many people who carry one never get cancer. For a cancer to start, more damage must build up inside a cell over many years. Only then does a tumor form. And only then does it begin to shed its changed DNA into the blood.
That is where the second kind of test comes in. Caris Detect and Galleri do not ask what you were born with. They ask, “Is something happening right now?”
Think back to the storm sirens. A born-with gene test is like a weather map. It shows whether you live where big storms are more common. A cancer blood test is like the siren. It sounds when a storm may already be forming. You want both: the map to know how closely to watch, and the siren to warn you in time.

Figure 6. The two kinds of DNA tests answer two different questions.
How These Tests Fit Your Watch-Tower
- A gene test is done once. Ask us about it if cancer runs in your family. That means cancer of the breast, ovary, colon, pancreas, or prostate in close relatives, or any cancer at a young age.
- It tells us how closely to watch. If we find a gene change, we build a stronger watch-tower for you. We may start tests at a younger age, do them more often, or add scans such as a breast MRI.
- It matters to your family, too. A gene change can be passed down. Your brothers, sisters, and children may want to be tested.
- A cancer blood test is part of the watching. It is done again each year, as Layer 2 of your plan.
- One test does not take the place of the other. Caris Detect reads all of your DNA, but it does not report on the genes you were born with. So a normal blood test does not tell you if you carry a gene change. And a person with a gene change still needs every extra check in their plan, even when the blood test is normal.
Evident — A Blood Test Just for Ovarian Cancer
Galleri and Caris Detect look for many cancers at once. In 2026, a new kind of blood test came into use that looks for just one: cancer of the ovary. It is called Evident.
We added it to our watch-tower for a simple reason. Ovarian cancer is one of the quietest cancers there is. And when it is found late, it is one of the hardest to beat.
Why Ovarian Cancer Is So Hard to Catch
The ovaries sit deep in the belly. A small tumor there does not hurt. The first signs are easy to brush off:
- Bloating that does not go away.
- Feeling full after only a few bites.
- A dull ache low in the belly or pelvis.
- Needing to pass urine more often.
Most women blame these on food, age, or stress. Many doctors do, too. And there is still no routine screening test for ovarian cancer. A Pap smear does not check for it.
Your Risk by Age
About 1 woman in every 91 will get ovarian cancer in her lifetime. This year, about 21,000 women in the United States will learn they have it. About 12,450 will die from it.
The risk is not the same at every age. It is rare in young women. It climbs after menopause. Half of all women who get ovarian cancer are 63 or older. Out of every 100 women found to have it:
- Under age 35 — about 6.
- Age 35 to 44 — about 8.
- Age 45 to 54 — about 16.
- Age 55 to 64 — about 24.
- Age 65 to 74 — about 24.
- Age 75 and older — about 22.

Figure 7. Ovarian cancer is found most often after menopause. About 7 out of every 10 cases are found at age 55 or older.
Some women carry a higher risk at any age. This is true if you carry a BRCA gene change, or if ovarian or breast cancer runs in your close family. That is one more reason we ask about your family story.
What Happens When It Is Found Late
Here is the hard truth. Only about 1 in 5 ovarian cancers is found early, while it is still inside the ovary. More than half are found after the cancer has already spread far.
When it is found makes all the difference:
- Found early, still inside the ovary — about 92 out of 100 women are alive 5 years later.
- Found after it has spread nearby — about 70 out of 100.
- Found after it has spread far — about 32 out of 100.

Figure 8. The same cancer, found at three different times. Finding it early changes the odds.
It is the same cancer each time. The only thing that changed is when it was found. That is the whole reason for a watch-tower.
How Evident Works
Evident does not look for cancer DNA. It looks for something else.
Every living cell sends out tiny bubbles. (Scientists call them extracellular vesicles.) Think of them as little notes in bottles. Each bubble wears marks on its outside from the cell that made it. The bubbles drift through the matrix around the cell and into the blood.
A very small tumor sheds very little DNA. But it sends out bubbles all day long. So the bubbles may give us an earlier warning.
Here is the hard part. Healthy cells send out bubbles too — far more of them. So how does the test tell them apart? Think of a lock that needs three keys at once. One key alone will not open it. Evident gives a signal only when it finds three cancer marks sitting together on the same bubble. A bubble from a healthy cell almost never wears all three.

Figure 9. One or two marks on a bubble mean nothing. All three marks on the same bubble set off the signal.
The test picks its three marks from a set of five. You do not need to remember the names, but here they are:
- MUC16 — a protein on the outside of ovarian cells. The older CA 125 blood test measures a piece of this same protein.
- MUC1 — a close cousin of MUC16. Many kinds of cancer cells wear too much of it.
- Folate receptor alpha — a doorway that lets the vitamin folate into a cell. Ovarian cancer cells build far too many of these doorways.
- BST2 — a protein that sits in the outer skin of a cell. Ovarian cancer cells make extra.
- STn — a sugar tag. Cancer cells often build their sugars the wrong way. This tag is one of the tell-tale mistakes.
How well does Evident work? The best study so far used blood saved from a very large screening trial in Great Britain. The blood came from more than 1,200 healthy women past menopause. For the women who later got cancer, it had been drawn up to a year before anyone knew. Evident flagged about 8 out of 10 of the most common and most deadly kind of ovarian cancer. The older CA 125 test, run on the same blood, flagged about 7 out of 10. In the women whose cancer was still at an early stage, Evident flagged 8 out of 9. That is a hopeful number, but it comes from a very small group.
But we must be honest about what we do not know yet.
- It can sound a false alarm. About 2 out of every 100 healthy women get a “signal detected” result. Ovarian cancer is not common. So for every woman whose signal turns out to be cancer, many more will have a false alarm.
- It can miss a cancer. In the study, it missed about 1 in 6 of the common kind. In an earlier study, it missed about 1 in 4 of the less common kinds.
- No one has shown yet that it saves lives. Finding ovarian cancer earlier should help. But an older screening plan in that same British trial found cancers sooner and still did not lower the number of deaths. A new study in the United States, called SOARA, has begun to test Evident in real time.
- The studies so far were paid for by the company that makes the test. University doctors in Great Britain took part in the largest one.
- It is not approved by the FDA yet. It is run in the company’s own lab. Ask us about the cost.
What Your Result Means
Your result will be one of two answers:
- Signal Not Detected — the test did not find the cancer marks. This is good news, but it is not an all-clear. If you have bloating, belly pain, or pelvic pain that lasts more than two or three weeks, tell us.
- Signal Detected — the test found bubbles wearing the cancer marks. This is not a diagnosis. Most women with this result do not have cancer. The next step is a pelvic ultrasound. We may also check your CA 125 and HE4 blood tests. No one goes to surgery because of a blood test alone.
Who Should Think About Evident
- Women past menopause who still have one or both ovaries. This is the group the test was studied in.
- Not yet younger women. The test has not been studied well in women before menopause.
- Women with a BRCA gene change or a strong family history need more. Evident has not been proven in this group. It does not take the place of the stronger plan your gene result calls for.
- It is an add-on. Galleri and Caris Detect cast a wide net for many cancers. Evident is a fine net for just one. It does not take the place of either.
How often? The test was made to be done once a year.
The Matrix Side of the Story
A test can only find trouble. It cannot stop it from starting. That is the job of Layer 1.
All through this book, we have said that cancer is not only a story about one bad cell. It is also a story about the ground that cell sits in — the matrix. A calm, strong matrix helps hold cells in place and keeps the messages between them clear. It is fitting that Evident reads the tiny bubbles cells send out through that very matrix.
This is why our watching always sits on top of the Expanded ECM Stabilizing Protocol —and low-dose naltrexone — along with the other matrix protocols in this book. We care for the ground first. Then we watch.
To be clear, this comes from what I have seen in my own patients over many years. It is not a promise. The protocol has not been tested against ovarian cancer in a study. It does not take the place of testing, and testing does not take the place of it. You need both: a well-kept matrix, and a watch-tower that never sleeps.

Click the picture above for more information about these supplements and how to purchase them.

Looking at the Heart — The Calcium Score
Heart disease is the biggest killer of both men and women in this country. About 1 person dies from heart and blood vessel disease every 34 seconds. And most of these deaths come from plaque — hardened, fatty gunk that has built up inside the heart’s arteries for decades.
The good news: we can see this plaque years before it causes any trouble. The test is called a coronary calcium score (sometimes shortened to CAC). It is a fast CT scan of the heart — takes about 10 to 15 minutes — and it counts the calcium specks in your heart’s arteries.

Figure 10. The calcium score shows how much hardened plaque is inside the heart’s arteries.
Here is what the numbers mean, in simple terms:
- Score of 0 — your heart’s arteries are clean. Very low risk for a heart attack in the next 10 years.
- Score of 1 to 99 — a little bit of plaque. We pay attention and work on prevention. Stop and stabilize further plaque formation
- Score of 100 to 300 — a fair amount of plaque. Time to be more aggressive with care.
- Score over 400 — a lot of plaque. High risk for a heart event. We act quickly to lower that risk.
How often? Most of our patients start with one calcium score around age 40 to 50. If it is zero or very low, we may not repeat for 5 to 10 years. If it is higher, we follow up sooner and treat what we find. We encourage cardiology visits.
Looking for Aneurysms
Brain Aneurysms
A brain aneurysm is a thin, weak spot on a blood vessel in the brain. It often looks like a tiny balloon. About 3 out of every 100 adults have one. Most never burst. But when they do, it can be very serious — about half of people who have a burst aneurysm do not survive, or have lasting harm.
We can screen for these upon request or clinical indications with a special scan called an MRA (magnetic resonance angiogram). It is much like a regular MRI but it makes clear pictures of the blood vessels. No X-rays, no needles in most cases.
Who should be screened? Most often, people who have:
- One or more close family members (parent, brother, sister, or child) who has had a brain aneurysm.
- A condition called polycystic kidney disease.
- A history of heavy smoking and high blood pressure together.
- Other strong risk factors that come up during your visits with us.
If you have two close family members who have had a brain aneurysm, your chance of having one is about 8 in 100 — much higher than the usual 3 in 100. For those folks, we suggest a screening MRA every 5 years. For people with one family member, every 10 years is usually enough.
Aortic Aneurysms
The aorta is the biggest blood vessel in your body. It carries blood from your heart down through your chest and belly. A weak spot on the aorta can swell up like a balloon — this is called an aortic aneurysm. If it bursts, it is almost always fatal.
The whole-body MRI we mentioned earlier already looks at the aorta in your chest and belly. So, for most patients, this part of the watch-tower is already covered. For men over 65 who have ever smoked, the rules also call for at least one ultrasound of the aorta in the belly area.
The Blood Tests We Add
Beyond Galleri, we order a set of blood tests once or twice a year to spot trouble early. These are simple, ordinary blood draws — but they tell us a lot.
Cancer and Cell Health
- Complete Blood Count (CBC) — looks at red blood cells, white blood cells, and platelets. Many cancers and blood problems show up here first.
- Comprehensive Metabolic Panel (CMP) — checks the kidneys, liver, sugar, and salts in your blood.
- CA 125 and HE4 with ROMA — for women, these help look for early ovarian cancer signals. For women past menopause, the Evident test described earlier can be added.
- PSA — for men, watches for prostate cancer.
- CEA, CA 19-9, AFP — tumor markers that can give early hints about colon, pancreas, or liver trouble.
Heart and Blood Vessel Health
- Full Lipid Panel with ApoB and Lp(a) — ApoB counts the harmful cholesterol particles. Lp(a) is a special kind of cholesterol passed down in your genes. Both predict heart attack risk far better than the old cholesterol numbers alone.
- hs-CRP — a marker of quiet body-wide inflammation. When it is high, the risk of heart trouble and many other diseases goes up.
- Homocysteine — high levels can damage blood vessels.
- Fasting glucose, hemoglobin A1C, and fasting insulin — catches diabetes and insulin trouble years before most doctors find it.
- NT-proBNP — an early signal that the heart muscle is under stress.
Other Important Checks
- Vitamin D, B12, folate, ferritin, iron studies — low levels are common and easy to fix, but they affect almost everything.
- Thyroid panel (TSH, free T3, free T4, antibodies) — the thyroid quietly drives energy, weight, mood, and heart health.
- Hormone panel — estrogens, progesterone, testosterone, DHEA, and cortisol. These shape almost every tissue in the body.
- Heavy metals screen — mercury, lead, arsenic, and others. These can build up quietly and stress the body for years.
- Urine test for kidney health and a glimpse of overall body waste — a simple but useful check.
How It All Fits Together
None of these tests alone is a magic answer. But together, they form a strong watch-tower. Each one catches what the others might miss. Here is how we put them in layers:

Figure 11. The five layers of your personal surveillance plan.
Layer 1 is prevention every day. Good food, daily movement, deep sleep, low stress, and the right supplements. This includes low-dose naltrexone (LDN), a small daily pill that helps your immune system stay alert. We have used it at the FEM Centre for many years and have seen it help patients stay well.

Layer 2 is a cancer DNA blood test — Galleri, Caris Detect, or the Guardant multi cancer blood test — once a year for most patients aged 50 and up. Most patients need only one of these. A one-time gene test for the risk you were born with, when your family story calls for it, helps us decide how closely to watch. For women past menopause, we may add Evident, the blood test just for ovarian cancer.
Layer 3 is the whole-body MRI — every 1 to 3 years, depending on your story.
Layer 4 is the coronary calcium score — a baseline scan, then follow-up depending on what we find. This catches the silent killer that beats every cancer combined when it comes to women’s lives lost.
Layer 5 is targeted vessel checks — the brain MRA and aorta scan when your family history, age, or risk factors tell us to look. Not everyone needs these. We tailor them to you.
What to Expect
Some patients worry about finding too much. “What if you find something small and it never would have hurt me?” That is a fair question. Here is how we handle it:
- We never act on a finding alone. We look at the whole picture — your symptoms, your other tests, your family story, and the size and behavior of the finding.
- Most small findings are watched, not treated. If a tiny cyst or spot is seen, we may just check it again in a year. Most fade or stay the same forever.
- We explain everything. You will never be alone with a scary word on a piece of paper. We sit down with you and walk through what each result means.
The Big Idea
The old way was to wait for symptoms and then react. The new way is to look on purpose, on schedule, with the best tools we have. Many of the worst illnesses we face are quiet for a long time before they speak. So we listen for them. We watch. We test. We catch them while they are still small — when there is still time to do something simple, easy, and effective.
That is what ‘Tis better to be seen than viewed means. We see you while you are well — so we never have to view you when it is too late.
References
1. GRAIL, Inc. PATHFINDER 2 results: multi-cancer early detection blood test increased cancer detection more than seven-fold when added to USPSTF A and B recommended screenings. Presented at ESMO Congress 2025; October 17-21, 2025; Berlin.
2. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177.
3. Schrag D, Beer TM, McDonnell CH 3rd, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-1260.
4. Centers for Disease Control and Prevention. Heart Disease Facts. Updated 2024. https://www.cdc.gov/heart-disease/data-research/facts-stats/
5. Centers for Disease Control and Prevention. About Women and Heart Disease. Updated 2024. https://www.cdc.gov/heart-disease/about/women-and-heart-disease.html
6. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347-913.
7. Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434-447.
8. Hecht HS. Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc Imaging. 2015;8(5):579-596.
9. Bos D, Vernooij MW, Elias-Smale SE, et al. Magnetic resonance imaging-based detection of incidental brain aneurysms in the general population. Ann Neurol. 2016;79(2):176-184.
10. Brown RD Jr, Broderick JP. Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. Lancet Neurol. 2014;13(4):393-404.
11. Bobak T, Kazimirsky G, Faintuch R, et al. Higher incidence of unruptured intracranial aneurysms among Black and Hispanic women on screening MRA. AJNR Am J Neuroradiol. 2023;44(5):574-580.
12. Cunqueiro A, Scheinfeld MH. Causes of misinterpretation of body MRI: a review of pitfalls. Insights Imaging. 2018;9(6):865-875.
13. Saunders CL, Sutcliffe L, Karthikeyan VJ, et al. Whole-body MRI screening: a systematic review of the literature. Br J Radiol. 2021;94(1118):20200970.
14. Petersen SE, Friedrich MG, Leiner T, et al. Cardiovascular magnetic resonance for patients with COVID-19. JACC Cardiovasc Imaging. 2022;15(4):685-699.
15. Younossi M, Pedersen NS, Tucker MD, et al. Low-dose naltrexone in the treatment of fibromyalgia and immune-mediated conditions. Clin Rheumatol. 2014;33(4):451-459.
16. Caris Life Sciences. Caris Life Sciences finalizes Achieve 1 study results reinforcing the superior sensitivity and specificity of Caris Detect [press release]. March 31, 2026.
17. Caris Life Sciences. Caris Detect multi-cancer early detection test: test information. Accessed November 2026. https://www.carislifesciences.com/carisdetect/
18. NHS-Galleri: primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening. J Clin Oncol. 2026;44(17 suppl):LBA100.
19. Manning BJ, Banerjee S, Hawkins TB, et al. Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples. Gynecol Oncol. 2025;203:26-34.
20. Winn-Deen ES, Bortolin LT, Gusenleitner D, et al. Improving specificity for ovarian cancer screening using a novel extracellular vesicle-based blood test: performance in a training and verification cohort. J Mol Diagn. 2024;26(12).
21. Mercy BioAnalytics. Mercy BioAnalytics receives FDA approval to initiate prospective pivotal study of Evident Ovarian Cancer Screening Test [press release]. September 21, 2026.
22. National Cancer Institute, SEER Program. Cancer Stat Facts: Ovarian Cancer. Accessed November 2026. https://seer.cancer.gov/statfacts/html/ovary.html
23. American Cancer Society. Key Statistics for Ovarian Cancer. Revised January 13, 2026. https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html
24. Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182-2193.
Important Note
This chapter shares information for patients and families. It does not take the place of medical care from your own doctor. The tests and ideas here are based on the best evidence available at the time of writing. No test is perfect. No screening program catches every illness. What matters most is the conversation between you and your care team — the layers in this chapter are tools we use to make that conversation as informed as it can be. The Galleri, Caris Detect, and Evident tests, whole-body MRI, and several supplements named in this book are not FDA-approved as preventive screening tools for the general public; they are used here based on clinical experience and growing evidence. The ECM Expanded Stabilizing Protocol, low-dose naltrexone, and other FEM Centre protocols mentioned are dietary supplements or off-label uses of FDA-approved medicines and are not intended to diagnose, treat, cure, or prevent any disease.
